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Bulleted novelty statement 
• This descriptive, retrospective study provides real-world data on the use of a second-
generation basal insulin, insulin glargine 300 units/mL (U300) in Type 1 DM across the 
UK. 
• Overall, participants who switched to U300 demonstrated improvements in HbA1c without 
significant changes in basal insulin dose and weight from baseline. 
• The number of participants with documented severe hypoglycaemia and diabetic 
ketoacidosis requiring A&E visits or hospitalization was low and similar prior to and after 
U300 initiation. 
• Results from this real-world study demonstrate that observations made in randomized 
controlled trials translate to people with Type 1 DM treated with U300 in clinical practice 
in the UK. 
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Abstract 
 
Aim     Insulin glargine 300 units/mL (U300) is a second-generation, once-daily basal insulin 
analogue. This open-label study provides UK real-world evidence from its use in Type 1 
diabetes mellitus (DM). 
 
Methods     Participants with Type 1 DM prescribed U300 ≥6 months before data collection 
with glycated haemoglobin (HbA1c) levels recorded within 3 months prior to U300 initiation 
(baseline) were included. The primary endpoint was change in HbA1c from baseline to Month 
6 after U300 initiation. Other endpoints included number of documented hypoglycaemic and 
diabetic ketoacidosis (DKA) episodes, and change in daily basal insulin dose. 
 
Results     A total of 298 people with Type 1 DM were included (mean age 42.1 years, mean 
HbA1c 79 mmol/mol [9.4%]). After U300 initiation, mean reduction in HbA1c from baseline to 
Month 6 was –4 mmol/mol (–0.4%; P<0.001; n=188). Total daily basal insulin dose at 6 
months was 1.3 units higher compared with U300 initiation (P<0.001; n=275) but was not 
significantly different from prior basal insulin dose. There was no clinically significant 
difference in weight between baseline and Month 6 (mean difference +0.7 kg [95% CI –0.1, 
1.5]; P=0.084; n=115). During the 6 months before and after U300 initiation, severe 
hypoglycaemic episodes were documented for 6/298 and 4/298 participants. DKA requiring 
A&E visits or hospitalizations were documented for 4/298 and 6/298 participants, before and 
after U300 initiation, respectively. 
 
Conclusions    In participants with Type 1 DM, a change in basal insulin to U300 was 
associated with clinically and statistically significant HbA1c improvements, without significant 
changes in basal insulin dose and weight. Documented severe hypoglycaemia episodes and 
DKA requiring A&E visits or hospitalizations were low and similar before and after U300 
initiation. 
Keywords: Insulin glargine 300 units; Type 1 diabetes mellitus; real-world evidence; 
hypoglycaemia 
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Introduction 
Insulin glargine 300 units/mL (U300; Toujeo®, Sanofi) is a second-generation, once-daily 
basal insulin analogue [1]. As a result of its distinct formulation, U300 has a discrete 
pharmacokinetic and pharmacodynamic profile when compared with insulin glargine 100 
units/mL (U100; Lantus®, Sanofi) [2, 3]. The higher concentration of U300 generates 
precipitate with a smaller surface area following subcutaneous injection compared with U100 
resulting in a steadier and extended glargine release and leading to a smoother 
pharmacokinetic profile and longer duration of action [1-3]. 
The use of U300 in people with Type 1 diabetes mellitus (DM) is supported by results 
from two phase III randomized controlled trials: EDITION 4 and EDITION JP 1 [4, 5]. 
However, no participants from the UK were included in these randomized controlled trials, 
and there is no real-world evidence on the use and utility of U300 in Type 1 DM in UK clinical 
practice. 
This study was designed to provide evidence on the effectiveness of U300 in people 
with Type 1 DM across the UK over a 6-month observation period.  
 
Methods  
A retrospective, observational, single-arm study was conducted in eight NHS centres across 
the UK. Anonymized participant-level data, corresponding to a predefined core data set, 
were collected from electronic medical notes and paper charts and entered into a database 
(compliant with the Code of Federal Regulations 21 Part 11 [6] and approved for use in the 
NHS setting). This study was conducted in accordance with the principles laid out by the 
18th World Medical Assembly (Helsinki, 1964) and all its subsequent amendments (up to 
2013), and with the International Society for Pharmacoepidemiology guidelines for Good 
Pharmacoepidemiology Practice, in accordance with local regulations, including local data 
protection regulations.  
 People with Type 1 DM who were prescribed their first dose of U300 ≥ 6 months 
before the date of data collection (01 August 2015) and had a glycated haemoglobin (HbA1c) 
blood result within 3 months prior to starting U300 were included. Data were collected 
retrospectively from 11 October 2017 to 7 December 2017.  
 Participants with Type 2 DM or participants with Type 1 DM who were insulin naïve, 
using an insulin pump, pregnant or participating in a concurrent clinical trial were excluded 
from participation. For evaluation of HbA1c at 3 months and all variables at 6 months, 
observation windows of 60–120 days (2–4 months) and 120–270 days (5–9 months) after 
U300 initiation, respectively, were permitted. Six-month treatment data prior to, and for 6 
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months following, initiation of U300 were analysed (Fig. 1). Participant eligibility was not 
determined by the availability of HbA1c data at 6 months post-initiation of U300. 
The primary endpoint was change in HbA1c from baseline to Month 6 after U300 
initiation. Secondary efficacy endpoints included change in HbA1c from baseline to Month 3 
after U300 initiation, change in basal, prandial and total (basal and prandial combined) daily 
insulin doses from previous insulin therapy (baseline) to Month 6 and from U300 initiation to 
Month 6, and change in weight from baseline to Month 6. Secondary safety endpoints 
including the number of hypoglycaemic episodes and diabetic ketoacidosis (DKA) episodes 
requiring A&E visits or hospitalizations during the 6 months prior to and following initiation of 
U300 were analysed, where documented. The following additional secondary endpoints 
were also extracted: reasons for switching or discontinuing previous diabetes therapy, and 
where appropriate, for discontinuing treatment with U300; the proportions of participants 
meeting the optimal titration dose of U300 (defined as the dose when the titration process 
was halted when adequate HbA1c or fasting plasma glucose [FPG] levels were achieved) 
and meeting individualized HbA1c targets during the observation period; diabetes education 
attendance; and change in insulin-to-carbohydrate ratio.  
Reliability estimates for the primary outcome for sample sizes ranging from 100 to 
400 participants suggested that, based on 99% confidence limits, the precision of estimates 
would not improve much above sample sizes of 200. For an observed HbA1c reduction of 3 
mmol/mol (0.3%) at this sample size, there would be 99% confidence that the true value 
would be greater than or equal to 2 mmol/mol (0.2%). As complete data records cannot be 
guaranteed in real-world settings, a sample size of 300 participants was considered 
sufficient to address the primary objective and to ensure inclusion of a wide variety of 
participants in terms of severity of disease, age, sex and geographical location.  
In order to minimize biases associated with the study and to reflect, as accurately as 
possible, a cross-section of clinical experience throughout the UK, the following measures 
were taken: Sites were enrolled from different healthcare systems (i.e. from community and 
tertiary centres) and geographical locations. A minimum of ten participants was required per 
site to ensure good geographical representation, while an enrolment cap of 100 participants 
per site was chosen to minimize the potential for centre bias. In addition, in order to avoid 
selection bias, participants were recruited in reverse consecutive order from the last eligible 
participant seen during the most recent clinic visit. Data heterogeneity was evaluated using a 
one-way ANOVA comparing change in HbA1c (the primary endpoint) between sites; no 
significant difference was found (P=0.137). Source data verification was performed to ensure 
quality, accuracy and consistency of the data collection. 
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Descriptive statistics (including the mean, standard deviation [SD], median and 
interquartile range) were calculated for quantitative variables with frequencies and 
percentages derived for qualitative variables (analysed using Stata v14 [StataCorp LLC]). 
Changes in participant measurements between time periods were evaluated using paired t-
tests. Analyses involving a within-participant change from baseline used only those data 
available at both time points (paired values). In addition to analysing endpoints with the 
overall population, change in HbA1c from baseline to 6 months (both univariate analysis and 
multivariate adjusting for sex, retinopathy and neuropathy) was also analysed for the 
‘completer-finisher’ subgroup population, which included participants who remained on 
treatment for at least 6 months post-initiation of U300 and for whom paired HbA1c data were 
available. Additional post hoc analyses included: a linear model comparing change in HbA1c 
from baseline to 6 months versus baseline HbA1c; change in HbA1c from baseline to Month 6 
for the subgroup of participants previously on once-daily basal insulin and for the subgroup 
of participants previously on twice-daily basal insulin (difference between subgroups 
calculated with and without an adjustment for baseline HbA1c); and the proportion of 
participants taking U300 as per the Summary of Product Characteristics[1]. 
 
Results 
Participant characteristics 
Three hundred people were screened; two were excluded (one was <18 years at initiation of 
U300, and one did not have a HbA1c measurement within 3 months of U300 initiation), 
leaving 298 participants with Type 1 DM eligible for inclusion in the final analysis (Fig. 1). 
Data are only listed for participants whose data were available in medical notes; therefore, 
not all the data points were present for all participants in the overall cohort (n=298). 
Participating NHS centres were located in England, Northern Ireland, Scotland and Wales 
(Table S1).  
Participants’ baseline characteristics are summarized in Table 1. The mean age of 
participants was 42.1 years, 51% were men and 72% were white. Participants had an 
average baseline HbA1c of 79 mmol/mol (9.4%), weight of 81.2 kg and body mass index 
(BMI) of 28.3 kg/m2. The mean time from diagnosis of diabetes to data collection was 21.6 
years. At baseline, 86% of participants were on a basal-bolus insulin regimen, 7% were on a 
basal insulin only and 5% were on pre-mixed insulin (Table 1). The most common basal 
insulins were U100 (55%) and insulin detemir (35%); insulin aspart (64%) and insulin lispro 
(20%) were the most commonly used rapid-acting insulins (Table 1). A total of 35% 
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(105/298) of participants were on an insulin regimen that included a twice-daily basal insulin 
component.  
 The mean (SD) total daily insulin dose (basal and prandial insulin combined) at baseline 
was 68.4 (37.1) units/day; the combination of mean basal and prandial insulin dose was 
approximately 50:50 (basal insulin: 35.9 [21.6] units/day, prandial insulin: 35.0 [23.0] 
units/day; Table 1). Of the 188 participants with both baseline and 6-month insulin doses 
available, 59% (110/188) were on a once-daily dosing regimen and 39% (73/188) were on a 
twice-daily dosing regimen (3% [5/188] had no previous dosing regimen recorded).  
Of diabetes-related comorbidities documented at baseline, retinopathy (33%) was the 
most common, followed by dyslipidaemia (23%), hypertension (18%) and depression (18%). 
Ninety-seven subjects (33%) provided no data on this measure (Table S2). Twenty-one (9%) 
participants with data recorded were documented as hypoglycaemic unaware at baseline 
(Table S3). 
 
Efficacy 
Change in HbA1c 
In the population for whom paired HbA1c values were available (n=188), HbA1c significantly 
decreased from baseline (78 mmol/mol [9.3%]) to Month 6 post-initiation of U300 (74 
mmol/mol [8.9%]), with a mean difference of −4 mmol/mol (95% CI −6.0, −2.4; [−0.4%, 95% 
CI −0.5%, −0.2%]; P<0.001; primary endpoint; Fig. 2a). In the ‘completer-finisher’ subgroup 
population, which includes participants who remained on treatment for at least 6 months 
post-initiation of U300 and for whom paired HbA1c data were available (n=175), a similar 
significant change in HbA1c of −4 mmol/mol (95% CI −6.2, −2.4; [−0.4%, 95% CI −0.6%, 
−0.2%]; P<0.001) was observed (Fig. 2b).  
A post hoc analysis of the change in HbA1c from baseline to 6 months versus 
baseline HbA1c indicated that for every 1 mmol/mol the baseline HbA1c was higher, the mean 
reduction in HbA1c at 6 months would increase by 0.27 mmol/mol (linear model; P<0.001; 
Fig. S1). This translates to an increased reduction of 0.27% for every increase in 1% in 
baseline HbA1c. This general relationship holds even after adjusting the analysis for other 
covariates associated with change in HbA1c (including sex, retinopathy and neuropathy). 
  For participants previously on once-daily basal insulin, according to a post hoc 
analysis, change in HbA1c from baseline to Month 6 was –3 mmol/mol (95% CI –5.1, –1.1; 
[−0.3%, 95% CI –0.5%, –0.1%]; P<0.01; n=110; Fig. 2c). For participants previously on 
twice-daily basal insulin, change in HbA1c from baseline to Month 6 was –6 mmol/mol (95% 
CI –9.8, –2.9; [−0.6%, 95% CI –0.9%, –0.3%]; P<0.001; n=73; Fig. 2d). HbA1c reductions 
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were significantly larger for participants previously on twice-daily versus once-daily basal 
insulin treatment after adjusting for differences in baseline HbA1c between the groups 
(unadjusted P=0.102; adjusted P=0.036).  
 At Month 3 post-initiation of U300, mean HbA1c fell from 80 mmol/mol (9.5%) at baseline 
to 74 mmol/mol (8.9%) with a significant mean change of –6 mmol/mol (95% CI –9.8, –2.5; 
[–0.6%, 95% CI –0.9%, –0.2%]; P=0.001; n=95; Fig. 3).  
 
Change in weight 
There was no clinically significant difference in weight between baseline and Month 6 (mean 
difference +0.7 kg [95% CI –0.1, 1.5]; P=0.084; n=115; Fig. 4a). The distribution of 
participants’ weight change and mean weight change from baseline to Month 6 after U300 
initiation are presented in Table S4. 
 
Change in basal, prandial and total daily insulin 
There was a significant increase in basal insulin dose of 1.3 units (P<0.001; n=275) from 
U300 initiation to 6 months. This followed a significant reduction in basal insulin dose from 
previous basal insulin therapy (baseline) to U300 initiation of –2.4 units (P<0.001), in line 
with the Summary of Product Characteristics guidance when switching to U300. However, 
the change in basal insulin dose was not significant between previous basal insulin therapy 
and 6 months post-initiation of U300 (–1.1 units; P=0.155; n=237; Fig. 4b–4d).  
A low number of dose changes of U300 were documented for participants after 
initiation; a mean (SD) of 0.8 (1.1) dose adjustments (median, 0.0 [range: 0–8]) was 
recorded. 
There was no significant difference in total daily prandial insulin dose or total daily 
insulin dose (basal and prandial combined) between previous insulin therapy (baseline) and 
Month 6 or U300 initiation and Month 6 (Figure S2). 
Most participants received U300 as part of a basal-bolus regimen 6 months post-
initiation of U300 (89% [265/298]); the remainder received U300 alone, with no prandial 
insulin component (5% [15/298]) or discontinued therapy (6% [18/298]). A post hoc analysis 
confirmed that all participants taking U300 were using it once daily, as per the Summary of 
Product Characteristics [1].  
 
Safety 
Documented severe hypoglycaemic episodes were experienced by 6/298 (2%) participants 
and 4/298 (1%) participants during the 6 months prior to and post-initiation of U300, 
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respectively (Table 2). Severe episodes requiring A&E visits or hospitalization and mild-to-
moderate hypoglycaemic episodes are shown in Table S5. 
DKA episodes requiring A&E visit or hospitalization were documented in 4/298 (1%) 
participants in the 6 months prior to initiation of U300 and 6/298 (2%) in the 6 months 
following initiation (Table 2). No participants with documented DKA episodes discontinued 
U300 during the 6 months post-initiation. 
 
Additional endpoints 
Reasons for switching from previous diabetes therapy prior to starting U300 and for 
discontinuing treatment with U300 are shown in Figure 5. The most common reasons for 
discontinuing previous basal insulin were lack of efficacy (157/271 [58%]) and 
hypoglycaemia concerns (57/271 [21%]). Twenty four participants had ‘not known’ as reason 
for discontinuation recorded. A total of 18 (6%) participants discontinued U300 by Month 6, 
the most common reason being difficulty with dosing (6/18 [33%]). 
The majority of participants (162/185 [88%]) did not meet recorded individualized 
HbA1c targets (Table S6). Limited data were obtained on whether participants reached the 
optimal titration of U300, and therefore meaningful conclusions could not be made (Table 
S7). Participation in structured diabetes education was recorded for 17/298 (6%) participants 
in the 6 months pre-initiation of U300 and 19/298 (6%) participants post-initiation of U300 
(Table S8). It is important to note that these proportions do not reflect the possibility that 
participants may have had structured education at an earlier point in their lives. Limited 
insulin-to-carbohydrate ratio data were available at baseline and at 6 months post-initiation 
of U300, and therefore definite conclusions could not be made about the level of insulin 
optimization achieved (Table S9). 
 
Discussion 
This descriptive, retrospective study documents the real-world experience of using U300 in 
people with Type 1 DM undergoing routine care across the UK. Overall, participants who 
switched to U300 demonstrated improvements in HbA1c, without significant changes in 
insulin dose or weight from baseline. Documented severe hypoglycaemia episodes and DKA 
events requiring A&E visits or hospitalization prior to and post-initiation of U300 were low or 
similar. These real-world outcomes, reflecting the real-life experience in UK practice, are 
broadly similar to those observed for U300 in EDITION 4, a randomized, controlled, treat-to-
target trial with comparable baseline characteristics of participants, with the exception of 
baseline HbA1c, which was higher in our study [4]. The higher baseline HbA1c observed in 
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this study was, however, similar to that reported by a National Diabetes Audit of UK 
practices [7], suggesting that this level of glycaemia is representative of the UK Type 1 DM 
population.  
Following the switch to U300, improvements in glycaemic control occurred relatively 
quickly and were seen across the 6-month treatment observation period (3 months: 6 
mmol/mol [0.6%] [n=95]; 6 months: 4 mmol/mol [0.4%] [n=188]). A post hoc analysis 
revealed a statistically significant greater reduction in HbA1c at 6 months for those 
participants who had been on twice-daily versus once-daily basal insulin prior to U300 
initiation when adjusted for baseline HbA1c (–6 mmol/mol [n=73] vs –3 mmol/mol [n=110]). 
These data suggest that poorly controlled patients moving from a twice-daily regimen to 
once-daily U300 not only benefited from a  improvement in HbA1c but also a reduction in the 
number of daily injections. 
There was a statistically significant increase (albeit small) in the mean daily dose of 
U300 from initiation to Month 6 of 1.3 units, which corresponded to an average of 0.8 dose 
adjustments per participant. Changes in total insulin (basal and prandial combined), basal 
insulin and prandial insulin dose from previous therapy dose (baseline) to 6 months were not 
significant, nor was the change in total insulin and prandial insulin dose from U300 initiation 
to Month 6. These observations were consistent with a pilot study (n=18) investigating the 
benefits of participants with Type 1 DM switching to U300 [8].  
There was no clinically significant change in weight at Month 6 after U300 initiation 
compared to baseline (prior insulin therapy), Although these results must be interpreted with 
caution because the evaluable sample size was small (n=115), similar findings were 
reported in the U300 pilot study (n=18) [8].  
In a post hoc analysis, it was observed that participants with a higher starting 
baseline HbA1c achieved a greater reduction in HbA1c, which is in line with observations 
reported for a number of therapeutic interventions in randomized controlled trials [9]. The 
linear relationship between baseline HbA1c and HbA1c reduction suggests that U300 provides 
a direct therapeutic benefit and that the reduction seen in the study after switching to U300 
cannot be explained by a simple ‘placebo effect’ of changing therapy. The improved 
glycaemic control observed with U300 may be due to the beneficial pharmacokinetic-
pharmacodynamic properties and improved 24-hour basal insulin coverage of U300 
compared to U100 as demonstrated in a continuous glucose monitoring study [10].  
The main reasons for switching from previous insulin for those participants with data 
recorded (n=247) were lack of efficacy (64%) and hypoglycaemia concerns (23%). This 
suggests that in clinical practice, improvement in glycaemic control remains an important 
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objective of treatment. After 6 months, 94% of participants remained on U300, indicating 
good tolerability of U300 when used in routine clinical practice. These observations are in 
agreement with the higher persistence observed with U300 in both Type 1 and Type 2 DM 
compared to other basal insulins in real-world study of basal insulin usage [11].  
Despite the improvement in HbA1c observed, few participants were described as 
achieving optimal titration or meeting individualized HbA1c targets. In contrast to the primary 
reason for changing basal insulin being to improve glycaemic control, the corresponding low 
average number of dose adjustments observed suggests that effective titration of insulin in 
clinical practice, even in experienced centres, is not achieved or sustained. In our study, 
HbA1c measurements were not systematically collected at the 6-month time point as was 
predicted to occur in routine practice given the National Institute for Health and Care 
Excellence guideline which recommends HbA1c testing every 3–6 months [12].  
It is possible that more motivated patients returned for 3-month and 6-month HbA1c 
checks, which could have biased the results. However, the inconsistent collection and 
recording of HbA1c measurements has also been seen in other UK data sets such as the 
National Diabetes Audit, where up to 17% of participants had HbA1c measurements missing 
over the last 15 months [13]. In addition to the potential issues of clinical inertia [14], 
individual factors such as adherence and motivation may affect outcomes. Of note, this 
study reported low recorded participation in structured diabetes education prior to and post-
initiation of U300, which may also have affected treatment response. Greater HbA1c 
reduction may have been achievable if there had been more intensive dose optimization with 
U300. 
It is well known that hypoglycaemia is under-reported and poorly recorded. Even 
severe hypoglycaemia may not be captured in clinical notes or routine clinical review; 
episodes requiring A&E visits or hospitalization have been demonstrated to go unreported to 
the direct care team in other real-world studies [15]. Data concerning hypoglycaemic events 
should be interpreted with caution in that 91% of participants prior to U300 initiation and 88% 
post-initiation of U300 had no documented mention of hypoglycaemia. Despite the low 
recorded hypoglycaemic frequency, hypoglycaemic concerns were cited in 21% of cases as 
the reason for basal insulin switch without documentation of events, adjustments of bolus 
insulin dose or referral to education. Compared to, and in parallel with the findings presented 
here, a recent prospective single-centre real-world study of participants with Type 1 DM in 
Belgium (n=116), which had a comparable population in terms of baseline BMI and weight 
but lower HbA1c (65 mmol/mol [8.0%] vs 80 mmol/mol [9.5%]), demonstrated a significant 
reduction in nocturnal hypoglycaemia after switching to U300 [16]. 
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Observational retrospective studies can be limited by real-world related biases with 
numerous (potentially unmeasureable) confounders. We have, however, sought to 
ameliorate these limitations through our study design. Following recruitment of 300 
participants and a final eligible population of 298, there was a smaller than expected 
evaluable sample size for the primary endpoint (n=188). However, a statistically significant 
change in HbA1c was observed, as the effect size was larger than anticipated. The smaller 
sample size marginally reduced the precision to answer descriptive endpoints. However, we 
performed an analysis to assess the homogeneity of the primary outcome and found that 
differences between sites were not significant; this suggests that the findings were robust 
across different centres. Additionally, source data verification was employed to enable 
correction of abstraction errors. Selected UK centres were known to be regular prescribers 
of U300 for participants with Type 1 DM; those that are not regular prescribers may have 
patients with different characteristics. Thus, generalizability was increased by ensuring 
adequate representation of UK sites and clinical settings, and a sample of 298 provides a 
good representative population and is a large sample size for this type of study [17]. In 
addition, we recognize that composite endpoints (e.g. those achieving a greater HbA1c 
reduction and weight loss) could not be evaluated as data points on both measurements 
were not always available for each participant. However, the conclusions for each individual 
endpoints are valid. 
In conclusion, statistically significant and clinically meaningful reductions in HbA1c at 
Month 6 (4 mmol/mol [0.4%] reduction) were observed following U300 initiation in a 
population of participants with Type 1 DM representative of clinical practice in the UK. The 
relationship between baseline HbA1c and the observed improvements in HbA1c may indicate 
that the improvement in glycaemic control is a direct effect of U300 treatment and might be 
due to the beneficial pharmacokinetic-pharmacodynamic properties and improved 24-hour 
basal insulin coverage of U300. This UK-based real-world study also suggests that there is 
an opportunity to more effectively manage people with Type 1 DM through more intensive 
follow-up, focussing on increased frequency of HbA1c measurements and insulin titration. 
Additionally, the observed missingness of data may be helpful in planning study size and 
power calculations in future real-world studies. Results of this real-world study demonstrate 
that observations made in randomized controlled trials on U300 in Type 1 DM translate to 
the population seen in everyday clinical practice within the UK. 
  
14 
 
References 
1 Toujeo® Summary of Product Characteristics. 2016. Available at 
https://www.medicines.org.uk/emc/medicine/30586. Last accessed 27 April 2018. 
2 Tillner J, Bergmann K, Teichert L, Dahmen R, Heise T, Becker RHA. Euglycemic clamp 
profile of new insulin glargine U300 formulation in patients with type 1 diabetes (T1DM) is 
different from glargine U100. Diabetes 2013; 62(Suppl 1): A234. Poster 920-P. Presented at 
the American Diabetes Association (ADA). 
3 Dahmen R, Bergmann K, Lehmann A, Tillner J, Jax T, Heise T et al. New insulin 
glargine U300 formulation evens and prolongs steady state PK and PD profiles during 
euglycemic clamp in patients with type 1 diabetes (T1DM). Diabetes 2013; 62(Suppl 1): 
A29. Poster 113-OR. Presented at the American Diabetes Association (ADA). 
4 Home PD, Bergenstal RM, Bolli GB, Ziemen M, Rojeski M, Espinasse M et al. New 
insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 1 diabetes: a 
randomized, phase 3a, open-label clinical trial (EDITION 4). Diabetes Care 2015; 38: 2217-
2225. 
5 Matsuhisa M, Koyama M, Cheng X, Takahashi Y, Riddle MC, Bolli GB et al. New insulin 
glargine 300 U/mL versus glargine 100 U/mL in Japanese adults with type 1 diabetes using 
basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled 
trial (EDITION JP1). Diabetes Obes Metab 2016; 18: 375-383. 
6 Code of Federal Regulations. Guidance for Industry Part 11, Electronic Records; 
Electronic Signatures — Scope and Application. 2003. Available at 
https://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm125125.pdf. Last 
accessed 01 May 2018. 
7 NHS Digital. National diabetes audit report 2016-17. 2018. Available at 
https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-
audit/insulin-pump-report-2016-17. Last accessed 28 June 2018. 
8 Gradišer M, Berkovic MC, Bilic-Curcic I. Changes in HbA1c and hypoglycemic episodes 
in type 1 diabetes patients after switching to insulin glargine U300: pilot study. Diabetes Res 
Clin Pract 2017; 129: 144-147. 
9 Giugliano D, Maiorino M, Bellastella G, Chiodini P, Esposito K. Relationship of baseline 
HbA1c, HbA1c change and HbA1c target of < 7% with insulin analogues in type 2 diabetes: 
a meta-analysis of randomised controlled trials. Int J Clin Pract 2011; 65: 602-612. 
10 Bergenstal RM, Bailey TS, Rodbard D, Ziemen M, Guo H, Muehlen-Bartmer I et al. 
Comparison of insulin glargine 300 units/mL and 100 units/mL in adults with type 1 diabetes: 
continuous glucose monitoring profiles and variability using morning or evening injections. 
Diabetes Care 2017; 40: 554-560. 
11 Quansah K, Sauriol L, Kukaswadia A, Bremner S, Millson B. Persistence with insulin 
glargine 300 IU/mL compared with other basal insulins—a Canadian retrospective cohort 
study. ADA 2018; 67(Suppl 1): Poster 1786-P. Presented at the American Diabetes 
Association (ADA). 
12 NICE. Type 1 diabetes in adults: diagnosis and management. 2015. Available at 
https://www.nice.org.uk/guidance/ng17/resources/type-1-diabetes-in-adults-diagnosis-and-
management-pdf-1837276469701. Last accessed 27 April 2018. 
13 NHS Digital. National Diabetes Audit Report 1 Care Processes and Treatment Targets 
2016-17. 2017. Available at https://digital.nhs.uk/catalogue/PUB30142. Last accessed 27 
April 2018. 
14 Khunti S, Davies MJ, Khunti K. Clinical inertia in the management of type 2 diabetes 
mellitus: a focused literature review. Br J Diabetes Vasc Dis 2015; 15: 65-69. 
15 Field B, Nayar R, Kilvert A, Baxter M, Hickey J, Cummings M et al. A retrospective 
observational study of people with type 1 diabetes with self-reported severe hypoglycaemia 
reveals high level of ambulance attendance but low levels of therapy change and specialist 
intervention. Diabet Med 2018: [Epub ahead of print]. 
15 
 
16 Oriot P, Jérémie W, Buysschaert M. Outcomes of glycemic control in type 1 diabetic 
patients switched from basal insulin glargine 100 U/mL to glargine 300 U/mL in real life. 
Expert Rev Endocrinol Metab 2018: 1-5. 
17 Karamat MA, Dar S, Bellary S, Tahrani AA. Clinical and cost implications of insulin 
degludec in patients with type 1 diabetes and problematic hypoglycemia: a Quality 
Improvement Project. Diabetes Ther 2018; 9: 839-849. 
 
  
16 
 
Table 1 Participant demographics and clinical characteristics at baseline*  
Characteristics  
Number of 
participants† 
Population  
(n=298) 
Age, mean (SD) years  298 42.1 (14.0) 
Men, n (%) 298 152 (51) 
Women, n (%) 298 146 (49) 
Ethnicity, n (%) 298  
White  216 (72) 
Other ethnic groups  16 (5) 
Not recorded  66 (22) 
Weight, mean (SD) kg 225 81.2 (20.9) 
BMI, mean (SD) kg/m2 161 28.3 (6.7) 
Height, mean (SD) cm 203 169.7 (10.2) 
Duration of diabetes at U300 initiation, years 272  
Mean (SD)  20.3 (12.9) 
Median (IQR)  17.9 (10.4–29.7) 
Duration of diabetes at data collection, years 272  
Mean (SD)  21.6 (13.0) 
Median (IQR)  19.3 (11.4–31.0) 
HbA1c 298  
Mean (SD) mmol/mol  79 (20.2) 
Mean (SD) %  9.4 (1.8) 
Hypoglycaemia and DKA   
Participants experiencing severe hypoglycaemia in  
last 6 months, n (%) 
298 6 (2) 
Participants experiencing DKA in last 6 months, n (%) 298 4 (1) 
Insulin regimen, n (%) 298  
Basal-bolus  257 (86) 
Pre-mix  16 (5) 
Basal insulin only  20 (7) 
Bolus (prandial) only  5 (2) 
Intermediate/long-acting insulin regimen, n (%) 277  
Basal-bolus with OD basal insulin  170 (61) 
Basal-bolus with BD basal insulin  84 (30) 
OD (basal insulin only)  9 (3) 
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BD (basal insulin only)  11 (4) 
Not recorded  3 (1) 
Rapid/short-acting insulin regimen, n (%) 262  
Basal-bolus/MDI  257 (98) 
Bolus only  5 (2) 
Pre-mix insulin regimen, n (%) 16  
OD  4 (25) 
BD  10 (63) 
Not recorded  2 (13) 
Insulin regimen, n (%) 298  
Insulin analogues   
Insulin aspart  192 (64) 
U100  164 (55) 
Insulin detemir  103 (35) 
Insulin degludec  6 (2) 
Insulin lispro  59 (20) 
Insulin glulisine  16 (5) 
Novomix 30 (insulin aspart protamine-insulin aspart)  6 (2) 
Humalog Mix 25/75 (insulin lispro protamine-insulin lispro)  3 (1) 
Humalog Mix 50/50 (insulin lispro protamine-insulin lispro)  2 (1) 
Human insulin   
Regular insulin  1 (<1) 
Humulin 30/70 (human insulin NPH-human insulin regular)  3 (1) 
Mixtard 30 (human insulin NPH-human insulin regular)  1 (<1) 
Humulin M3 (human insulin-isophane insulin)  2 (1) 
Insulatard (isophane insulin)  4 (1) 
Isophane insulin  7 (2) 
Insuman Comb (neutral insulin-isophane insulin)  1 (<1) 
Daily insulin dose, mean (SD) units/day   
Basal insulin 237 35.9 (21.6) 
Prandial insulin 136 35.0 (23.0) 
Total daily insulin (basal insulin plus prandial) 133 68.4 (37.1) 
BD, twice-daily; BMI, body mass index; DKA, diabetic ketoacidosis; HbA1c, glycated 
haemoglobin; IQR, interquartile range; MDI, multiple dose injection; NPH, Neutral Protamine 
18 
 
Hagedorn; OD, once-daily; SD, standard deviation; U100, insulin glargine 100 units/mL; 
U300, insulin glargine 300 units/mL. 
*Baseline variables were defined as the most recent observation within the 6-month period 
prior to U300 initiation, with the exception of baseline HbA1c, BMI, height and weight, which 
were defined as the most recent observation within the 3-month period prior to U300 
initiation.  
†Participants with data available at baseline. 
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Table 2 Incidence of severe hypoglycaemia and DKA episodes in the 6 months prior to and 
6 months after U300 initiation 
 Prior to U300 initiation Following U300 initiation 
Severe documented hypoglycaemia episodes 
 n % (n=298) N % (n=298) 
Number of episodes 7  4  
Number of participants with 
episodes 
6 2 4 1 
Mean (SD) episodes per 
participant 
0.02 (0.17) 0.01 (0.12) 
DKA episodes requiring A&E visits or hospitalization 
 n % (n=298) N % (n=298) 
Number of episodes 4  9  
Number of participants with 
episodes 
4 1 6 2 
A&E, Accident and Emergency Department; DKA, diabetic ketoacidosis; SD, standard 
deviation; U300, insulin glargine 300 units/mL.  
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FIGURE 1 Participant screening and eligibility. 
 
  
 
HbA1c, glycated haemoglobin; U300, insulin glargine 300 units/mL. 
*The primary endpoint population included all participants with HbA1c available both within 3 
months pre-initiation and at Month 6 post-initiation, irrespective of whether they had 
discontinued U300 by Month 6. 
†The primary endpoint subpopulation included participants with ongoing U300 therapy at 
Month 6 with HbA1c available both within 3 months pre-initiation and at Month 6 post-
initiation if they remained on U300 at Month 6.  
 
  
21 
 
FIGURE 2 Change in HbA1c from baseline to Month 6 post-initiation of U300 in (a) the overall 
population (primary endpoint), (b) the ‘completer-finisher’ subgroup population, (c) the 
subgroup of participants previously on once-daily basal insulin and (d) the subgroup of 
participants previously on twice-daily basal insulin. 
 
 
 
 
CI, confidence interval; HbA1c, glycated haemoglobin; SD, standard deviation; U300, insulin 
glargine 300 units/mL. 
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FIGURE 3 Change in HbA1c from baseline to Month 3 post-initiation of U300 in the overall 
population 
 
 
 
CI, confidence interval; HbA1c, glycated haemoglobin; SD, standard deviation; U300, insulin 
glargine 300 units/mL. 
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FIGURE 4 Change in (a) body weight from baseline to Month 6 post-initiation of U300, (b) 
total daily basal insulin dose from previous insulin therapy (baseline) to U300 initiation, (c) 
total daily basal insulin dose from previous insulin therapy (baseline) to Month 6 post-
initiation of U300 and (d) total daily basal insulin dose from U300 initiation to Month 6 post-
initiation of U300.  
 
  
 
 
CI, confidence interval; HbA1c, glycated haemoglobin; SD, standard deviation; U300, insulin 
glargine 300 units/m. 
P values were calculated according to paired t-test. 
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FIGURE 5 Reason for (a) switching from previous basal insulin therapy to U300* and (b) 
discontinuing U300 after initiation. 
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U300, insulin glargine 300 units/mL. 
*A total of 27 participants had no documented data available for reason for switching from 
previous basal insulin therapy to U300; these participants were not included in the total n 
value (n=271). 
†No additional information was provided for the 6% who discontinued U300 due to dosing 
difficulty. 
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Supplementary Table S1 Proportion of participants by county 
 
Proportion of participants 
n (%) 
(n=298) 
England 171 (57) 
Essex 37 (12) 
Surrey 32 (11) 
Sheffield 59 (20) 
West Midlands 43 (14) 
Northern Ireland 83 (28) 
County Down and 
Antrim 
33 (11) 
Derry and Antrim 50 (17) 
Scotland 14 (5) 
Glasgow 14 (5) 
Wales 30 (10) 
Swansea 30 (10) 
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Supplementary Table S2 Diabetes-related comorbidities at baseline 
 
Overall participant population 
(n=298) 
Diabetes-related comorbidities per 
participant  
 
Number per participant, n (%)  
0 97 (33) 
1 77 (26) 
2 62 (21) 
3 34 (11) 
4 18 (6) 
5 6 (2) 
6 2 (1) 
7 2 (1) 
Mean (SD) per participant 1.4 (1.4) 
Median per participant 1.0 
IQR 0.0–2.0 
Range 0.0–7.0 
Diabetes-related comorbidities, n (%)  
Obesity 43 (14) 
Dyslipidaemia 70 (23) 
Hypertension 54 (18) 
Cardiovascular disease 21 (7) 
Depression 53 (18) 
Kidney disease (nephropathy) 22 (7) 
Retinopathy 99 (33) 
Neuropathy 28 (9) 
Coeliac disease 9 (3) 
Thyroid disease 32 (11) 
None recorded 97 (33) 
Comorbidities are not mutually exclusive. 
IQR, interquartile range; SD, standard deviation. 
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Supplementary Table S3 Hypoglycaemic awareness status at baseline 
 Proportion of 
participants 
n (%) 
Hypoglycaemic awareness status n=298 
Hypoglycaemic aware 212 (71) 
Hypoglycaemic unaware 21 (7) 
Not known 65 (22) 
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Supplementary Table S4 Distribution of participants’ weight change and mean weight 
change between baseline and Month 6 post-initiation of U300 
Changes in weight from baseline to Month 6 post-initiation of U300 
Weight change in overall participant population (n = 298)  n (%) 
Lost weight 53 (18) 
Gained weight 59 (20) 
No weight change 3 (1) 
Weight not recorded 183 (61) 
Change in weight for participants losing or gaining weight Mean (SD) 
Weight lost, kg (n=53) –3.0 (2.6) 
Weight gained, kg (n=59) 4.7 (5.8) 
SD, standard deviation; U300, insulin glargine 300 units/mL. 
Baseline for weight was defined as the most recent observation within the 3-month period 
prior to U300 initiation. 
 
  
30 
 
Supplementary Table S5 Mild-to-moderate and severe hypoglycaemia episodes requiring 
A&E visits or hospitalization prior to and following U300 initiation 
 Documented hypoglycaemia episodes  
(n = 298) 
 Number of episodes  
n 
Proportion of participants 
n (%) 
No documented episodes 
Prior to U300 initiation  270 (91) 
Post U300 initiation  262 (88) 
Mild-to-moderate hypoglycaemia 
Prior to U300 initiation 39 11 (4) 
Post U300 initiation 86 27 (9) 
Severe hypoglycaemia episodes requiring A&E visits or hospitalization 
Prior to U300 initiation 4 3 (1) 
Post U300 initiation 1 1 (<1) 
A&E, Accident and Emergency Department; U300, insulin glargine 300 units/mL. 
All episodes refer to those that were documented. Mild-to-moderate and severe categories 
not mutually exclusive. 
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Supplementary Table S6 Proportion of participants who met an individualized HbA1c target 
during the observation period following initiation of U300 
 Proportion of participants  
n (%)  
Proportion meeting documented HbA1c targets  n=298 
Yes 23 (8) 
No 162 (54) 
Not known 113 (38) 
Reasons where not known  n=113 
No target recorded 87 (29) 
No post-initiation HbA1c 0 
No target and no post-initiation HbA1c 26 (9) 
HbA1c, glycated haemoglobin; U300, insulin glargine 300 units/mL. 
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Supplementary Table S7 Proportion of participants meeting their optimal titration dose 
following initiation of U300 
 Proportion of participants 
n (%) 
Proportion reaching optimal titration n = 298 
Yes 40 (13) 
No 51 (17) 
Not known 207 (69) 
Glycaemic parameter on which 
optimal titration of dose was based 
n = 40 
HbA1c 8 (20) 
FPG 21 (53) 
Both 7 (18) 
Not known 4 (10) 
FPG, fasting plasma glucose; HbA1c, glycated haemoglobin; U300, insulin glargine 300 
units/mL. 
*Optimal titration dose was defined as the dose at which a set target of HbA1c or FPG was 
achieved. 
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Supplementary Table S8 The proportion of participants who attended structured diabetes 
education at baseline and within 6 months after the initiation of U300, and the types of 
education used 
 Prior to U300 
initiation  
n (%) 
Following U300 
initiation 
 n (%) 
Structured diabetes education n=298 n=298 
Yes 17 (6) 19 (6) 
No 268 (90) 265 (89) 
Not known 13 (4) 14 (5) 
Type of education n=17 n=19 
DAFNE 5 (29) 9 (47) 
BERTIE/CHOICE* 4 (24) 4 (21) 
WICKED 0 0 
STEPH 4 (24) 2 (11) 
DAFYDD 2 (12) 2 (11) 
One-to-one with dietitian 1 (6)  
3-h carbohydrate counting course  2 (11) 
Not recorded 1 (6)  
*BERTIE and CHOICE are combined patient numbers 
BERTIE, Beta Cell Education Resources for Training in Insulin and Eating; CHOICE, CHO 
and Insulin Calculation Education; DAFNE, Dose Adjustment for Normal Eating; DAFYDD, 
Dose Adjustment for your Daily Diet; STEPH, Structured Education for People with Type 1 
Diabetes; U300, insulin glargine 300 units/mL; WICKED, Working with Insulin, Carbs, 
Ketones and Exercise to manage Diabetes.  
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Supplementary Table S9 Change in ICR from baseline to Month 6 post-initiation of U300 
Change in ICR by Month 6 
Overall participant 
population 
n (%) 
Participants with ICR 
recorded 
n (%) 
 n=298 n=27 
Increased ICR 6 (2) 6 (22) 
Decreased ICR 2 (1) 2 (7) 
No change 19 (6) 19 (70) 
ICR not recorded  271 (91)  
ICR, insulin-to-carbohydrate ratio; U300, insulin glargine 300 units/mL. 
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Supplementary Figure S1 Linear model comparing change in HbA1c (from baseline to 
Month 6 post-initiation of U300) to baseline HbA1c 
 
  
HbA1c, glycated haemoglobin; U300, insulin glargine 300 units/mL. 
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Supplementary Figure S2 Change in total daily prandial insulin dose and total daily insulin 
dose (basal plus prandial) from previous insulin therapy (baseline) to 6 months following 
U300 initiation, and from U300 initiation to Month 6 post-initiation 
 
 
 
CI, confidence interval; SD, standard deviation; U300, insulin glargine 300 units/mL. 
Participants with paired data. 
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STROBE Statement—checklist of items that should be included in reports of observational 
studies 
 
 
 Item 
No 
 
Recommendation 
Page No. 
Title and abstract 
 1 (a) Indicate the study’s design with a commonly used term in the 
title or the abstract  
Included P.1 
  (b) Provide in the abstract an informative and balanced summary 
of what was done and what was found  
Included, P.4 
Introduction 
Background/rationale 2 Explain the scientific background and rationale for the 
investigation being reported 
Included, P.5 
Objectives 3 State specific objectives, including any prespecified hypotheses Included, P.5 
Methods 
Study design 4 Present key elements of study design early in the paper Included, P.5 
Setting 5 Describe the setting, locations, and relevant dates, including 
periods of recruitment, exposure, follow-up, and data collection 
Included, P.5 
Participants 6 (a) Cohort study—Give the eligibility criteria, and the sources 
and methods of selection of participants. Describe methods of 
follow-up 
Case-control study—Give the eligibility criteria, and the sources 
and methods of case ascertainment and control selection. Give 
the rationale for the choice of cases and controls 
Cross-sectional study—Give the eligibility criteria, and the 
sources and methods of selection of participants 
Included, P.5 
  (b) Cohort study—For matched studies, give matching criteria 
and number of exposed and unexposed 
Case-control study—For matched studies, give matching criteria 
and the number of controls per case 
Data was paired - 
i.e. patients with 
starting and end 
measurement) 
Variables 7 Clearly define all outcomes, exposures, predictors, potential 
confounders, and effect modifiers. Give diagnostic criteria, if 
applicable 
Included, P.6 
Data sources/ 
measurement 
8* For each variable of interest, give sources of data and details of 
methods of assessment (measurement). Describe 
comparability of assessment methods if there is more than one 
group 
Included, P.7 
Bias 9 Describe any efforts to address potential sources of bias Included, P. 6 (also 
discussed in the 
discussion) 
Study size 10 Explain how the study size was arrived at Included, P.6 
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. 
If applicable, describe which groupings were chosen and why 
Included, P.7 
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Statistical methods 12 (a) Describe all statistical methods, including those used to 
control for confounding 
Included, P.7 
  (b) Describe any methods used to examine subgroups and 
interactions 
Included, P.7 
  (c) Explain how missing data were addressed Included, P.7 
  (d) Cohort study—If applicable, explain how loss to follow-up 
was addressed 
Case-control study—If applicable, explain how matching of 
cases and controls was addressed 
Cross-sectional study—If applicable, describe analytical 
methods taking account of sampling strategy 
Data was paired - 
i.e. patients with 
starting and end 
measurement) 
  (e) Describe any sensitivity analyses Sensitivity 
analyses not 
performed 
  Results 
Participants 
 
13* (a) Report numbers of individuals at each stage of study—eg 
numbers potentially eligible, examined for eligibility, confirmed 
eligible, included in the study, completing follow-up, and 
analysed 
Included, P.7 
  (b) Give reasons for non-participation at each stage Included, P.7 
  (c) Consider use of a flow diagram Included (See 
Figure 2) 
Descriptive data 
 
14 (a) Give characteristics of study participants (eg demographic, 
clinical, social) and information on exposures and potential 
confounders 
Included, P.7 
  (b) Indicate number of participants with missing data for each 
variable of interest 
Done through 
results text and/or 
in provided data 
tables 
  (c) Cohort study - Summarise follow-up time (eg, average and 
total amount) 
 
Results provided 
with timeframes 
Outcome data 
 
15* Cohort study—Report numbers of outcome events or summary 
measures over time 
Results provided 
with timeframes 
  Case-control study—Report numbers in each exposure 
category, or summary measures of exposure 
  Cross-sectional study—Report numbers of outcome events or 
summary measures 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-
adjusted estimates and their precision (eg, 95% confidence 
interval). Make clear which confounders were adjusted for and 
why they were included 
Included, P.9 
  (b) Report category boundaries when continuous variables were 
categorized 
Results provided 
with timeframes 
  (c) If relevant, consider translating estimates of relative risk into 
absolute risk for a meaningful time period 
Not relevant 
Other analyses 17 Report other analyses done—eg analyses of subgroups and 
interactions, and sensitivity analyses 
Post hoc analyses 
etc. reported within 
results section 
39 
 
Discussion 
Key results 18 Summarise key results with reference to study objectives Included, P.10 
Limitations 19 Discuss limitations of the study, taking into account sources of 
potential bias or imprecision. 
Discuss both direction and magnitude of any potential bias 
 
Included, P.12 
Interpretation 20 Give a cautious overall interpretation of results considering 
objectives, limitations, multiplicity of analyses, results from 
similar studies, and other relevant evidence 
Done throughout 
discussion 
Generalisability 21 Discuss the generalisability (external validity) of the study results Included, P.13 
Other information 
Funding 22 Give the source of funding and the role of the funders for the 
present study and, if applicable, for the original study on which 
the present article is based 
Included, P.3 
*Give information separately for cases and controls in case-control studies and, if applicable, for 
exposed and unexposed groups in cohort and cross-sectional studies 
Note: An Explanation and Elaboration article discusses each checklist item and gives 
methodological background and published examples of transparent reporting. The STROBE 
checklist is best used in conjunction with this article (freely available on the Web sites of PLoS 
Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, 
and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at 
www.strobe-statement.org. 
 
 
 
